What is Zacks Small Cap’s Estimate for COCP Q3 Earnings?

Cocrystal Pharma, Inc. (NASDAQ:COCP) – Zacks Small Cap issued their Q3 2025 earnings per share (EPS) estimates for shares of Cocrystal Pharma in a research report issued to clients and investors on Tuesday, April 1st. Zacks Small Cap analyst D. Bautz anticipates that the company will post earnings of ($0.45) per share for the quarter. The consensus estimate for Cocrystal Pharma’s current full-year earnings is ($1.85) per share. Zacks Small Cap also issued estimates for Cocrystal Pharma’s Q4 2025 earnings at ($0.36) EPS and FY2027 earnings at ($1.20) EPS.

Separately, HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Cocrystal Pharma in a research report on Wednesday, January 22nd.

Cocrystal Pharma Trading Up 0.7 %

Shares of COCP stock opened at $1.43 on Wednesday. The company has a market cap of $14.55 million, a PE ratio of -0.77 and a beta of 2.35. The company’s fifty day simple moving average is $1.77 and its 200-day simple moving average is $1.92. Cocrystal Pharma has a 52 week low of $1.35 and a 52 week high of $3.26.

Cocrystal Pharma (NASDAQ:COCP) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.23.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.